USANA Health Sciences, Inc. (USNA) SEC Filings & Earnings Calls
EquiReason read 13 USANA Health Sciences, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-10-05 — USANA amended its credit agreement, increasing leverage via a material direct financial obligation..
Source: SEC EDGAR filings · figures as of 2026-07-04 · read by EquiReason
- Market cap
- 257.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
5 Oct 20268-K · 1.01, 2.03USANA amended its credit agreement, increasing leverage via a material direct financial obligation.open
Risks flagged
Increased leverage from credit facility amendment; no specific financial impact disclosed.
“Item 2.03: took on a material direct financial obligation, increasing leverage.”
13 Aug 202610-QUSANA reported a Q2 net loss of $21.4M vs prior-year profit of $9.7M, with revenue down 5.3% and a $29.1M goodwill impairment in Hiya.open
Figures in the filing · each found in the filing text
| Consolidated Net Sales · Q2-2026 | $223M | -5% y/y |
| Core Nutritional Net Sales · Core Nutritional · Q2-2026 | $192M | -4% y/y |
| Hiya Net Sales · Hiya · Q2-2026 | $28M | -17% y/y |
| Rise Net Sales · Rise · Q2-2026 | $3M | +40% y/y |
| Core Nutritional Active Customers · Core Nutritional · Q2-2026 | 384,000 | -8% y/y |
| Hiya Active Monthly Subscribers · Hiya · Q2-2026 | 166,000 | -17% y/y |
| Goodwill Impairment Charge · Hiya · Q2-2026 | $29M | |
| Net Loss Attributable to USANA · Q2-2026 | $-21M |
Risks flagged
Core Nutritional customer attrition
“As of July 4, 2026, we had approximately 384,000 active Customers worldwide in the Core Nutritional business... 418,000... (34,000) (8.1%).” · word for word
Hiya goodwill impairment risk
“the Company recorded a non-cash goodwill impairment charge of $29.1 million during second quarter of 2026.” · word for word
Digital marketing headwinds
“The decrease was driven by a challenging digital marketing environment, which created pressure in both net sales and subscriber growth.” · word for word
4 Aug 20268-K · 2.02, 7.01Q2 2026 net sales $223M vs $236M YoY; net loss $(21.4)M including $29.1M impairment; adjusted EPS $(0.07) vs $0.74; guidance cut across all segments.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Consolidated · Q2-2026 | $223M | -6% y/y |
| Net loss · Consolidated · Q2-2026 | $-21M | -321% y/y |
| Diluted EPS · Consolidated · Q2-2026 | $-1.16 | -323% y/y |
| Adjusted diluted EPS · Consolidated · Q2-2026 | $-0.07 | -109% y/y |
| Adjusted EBITDA · Consolidated · Q2-2026 | $28M | -9% y/y |
| Core Nutritional Active Customers · Core Nutritional · Q2-2026 | 384,000 | -8% y/y |
| Hiya Active Monthly Subscribers · Hiya Health · Q2-2026 | 166,000 | -17% y/y |
| Cash and cash equivalents · Consolidated · Q2-2026 | $169M | |
| Inventory · Consolidated · Q2-2026 | $95M | |
| Share repurchase authorization remaining · Consolidated · Q2-2026 | $34M |
Guidance
FY2026: Core Nutritional net sales $750M (prev $720-$765M); Hiya net sales $125M (prev $140-$155M); Rise Wellness net sales $35M (prev $65-$80M); Consolidated net sales $910M (prev $925M-$1.0B); Net loss $(11)M (prev $20M-$27M); Diluted EPS $(0.61) (prev $1.11-$1.45); Adjusted diluted EPS $0.76 (prev $1.95-$2.29); Adjusted EBITDA $87M (prev $101M-$109M)
Guidance cut across all segments due to underperformance at Hiya and Rise; management cites temporary challenges but lowered expectations significantly.
Risks flagged
Customer attrition in core business and ventures.
“Core Nutritional active customers down 8% YoY; Hiya subscribers down 17%.”
Impairment charge indicates asset write-downs.
“$29.1M non-cash impairment charge.”
Guidance cut across all segments signals worsening outlook.
“Consolidated net sales guidance cut to $910M from $925M-$1.0B; adjusted EBITDA to $87M from $101M-$109M.”
12 May 202610-QNet Sales $250M (+0% y/y); Net Income Attributable to USANA $8M (-20% y/y); Core Nutritional Active Customers 404,000 (-12% y/y)open
Figures in the filing · each found in the filing text
| Net Sales · Consolidated · Q1-2026 | $250M | +0% y/y |
| Net Income Attributable to USANA · Consolidated · Q1-2026 | $8M | -20% y/y |
| Core Nutritional Active Customers · Core Nutritional · Q1-2026 | 404,000 | -12% y/y |
| Hiya Active Monthly Subscribers · Hiya · Q1-2026 | 186,000 | -17% y/y |
| Gross Profit Margin · Consolidated · Q1-2026 | 76.2% | |
| Diluted EPS · Consolidated · Q1-2026 | $0.41 | -16% y/y |
| Operating Cash Flow · Consolidated · Q1-2026 | $10M | -37% y/y |
| Cash and Cash Equivalents · Consolidated · Q1-2026 | $163M | |
| Effective Tax Rate · Consolidated · Q1-2026 | 55.0% |
Risks flagged
Core Nutritional Customer Decline
“The decrease in Core Nutritional net sales was mainly due to a 12.0% decrease in active Customers” · word for word
Hiya Customer Acquisition Slowdown
“The decrease was primarily the result of a lower customer base and a decrease in customer acquisitions.” · word for word
China Profit Repatriation Risk
“If SAFE or other Chinese regulators introduce new regulations or change existing regulations which allow foreign investors to remit profits and dividends earned in China to other countries, our ability to remit profits or pay dividends from China to the United States may be limited in the future.” · word for word
5 May 20268-K · 2.02, 7.01Q1 2026 net sales flat at $250M; net earnings down 20% to $7.5M; adjusted EPS down 16% to $0.61; active customers declining; reiterates FY2026 guidance across all metrics.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Consolidated · Q1-2026 | $250M | 0% y/y |
| Net earnings · Consolidated · Q1-2026 | $8M | -20% y/y |
| Diluted EPS · Consolidated · Q1-2026 | $0.41 | -16% y/y |
| Adjusted diluted EPS · Consolidated · Q1-2026 | $0.61 | -16% y/y |
| Adjusted EBITDA · Consolidated · Q1-2026 | $28M | -5% y/y |
| Core Nutritional Active Customers · Core Nutritional · Q1-2026 | 404,000 | -12% y/y |
| Hiya Active Monthly Subscribers · Hiya Health · Q1-2026 | 186,000 | -17% y/y |
| Core Nutritional net sales · Core Nutritional · Q1-2026 | $204M | -3% y/y |
| Hiya net sales · Hiya Health · Q1-2026 | $32M | -13% y/y |
| Rise Wellness net sales · Rise Wellness · Q1-2026 | $14M | +741% y/y |
Guidance
FY2026: Core Nutritional net sales $720-765M; Hiya net sales $140-155M; Rise Wellness net sales $65-80M; Consolidated net sales $925M-$1.0B; Net earnings $20-27M; Diluted EPS $1.11-1.45; Adjusted diluted EPS $1.95-2.29; Adjusted EBITDA $101-109M
Company reiterates all FY2026 guidance metrics; management expresses confidence in strategic direction and growth catalysts
Risks flagged
Core customer base declining; active customers down 12% YoY in Core Nutritional and 17% in Hiya
“Core Nutritional Active Customers 404,000 vs 459,000; Hiya Active Monthly Subscribers 186,000 vs 224,000”
Profitability pressure from investment spending and mix shift to lower-margin Rise Wellness
“Net earnings -20%; Adjusted EBITDA -5%; margin compression despite flat revenue”
7 Apr 2026DEF 14ACEO transition: Jim Brown stepped down, Kevin Guest reappointed CEO on Jan 8, 2026.open
Figures in the filing · each found in the filing text
| Core Nutritional Net Sales (constant currency) · Core Nutritional · FY2025 | $779M | -8% y/y |
| Core Nutritional Adjusted Operating Profit · Core Nutritional · FY2025 | $57M | |
| Hiya Net Sales · Hiya · FY2025 | $132M | |
| Hiya EBITDA · Hiya · FY2025 | $22M | |
| Consolidated Net Sales Growth · FY2025 | 8.3% | |
| Operating Cash Flow · FY2025 | $22M | |
| Cash and Cash Equivalents · FY2025 | $158M | |
| Net Income · FY2025 | $11M | -74% y/y |
| Operating Profit · FY2025 | $37M | -44% y/y |
| Total Shareholder Return (Cumulative, 5-year) · FY2025 | $25.00 |
Risks flagged
Core business revenue decline
“We achieved Fiscal Year 2025 constant currency core nutritional net sales of $779 million, which is an 8.0% decrease compared to Fiscal Year 2024” · word for word
Profitability deterioration
“Net income $ in thousands ... 2025 ... $10,760 ... 2024 ... $42,030”
Low bonus payout signals weak performance
“the Compensation Committee determined that each executive had earned a cash bonus under the 2025 Bonus Plan equal to 14.6% of the executive’s 2025 base salary” · word for word
PSU cancellation indicates missed targets
“As of the end of the vesting period, the market and performance conditions for the 2023 PSUs were not achieved, therefore the 2023 PSUs were cancelled in February 2026.” · word for word
CEO transition uncertainty
“On January 8, 2026, Mr. Brown stepped down as Chief Executive Officer and President and Mr. Guest reassumed the role of Chief Executive Officer while remaining Chairman.” · word for word
16 Mar 202610-KProduct returns as % of net sales 0.8; Auto Order as % of direct sales product sales volume 62; In-house manufacturing as % of product sales 56open
Figures in the filing · each found in the filing text
| Product returns as % of net sales · FY2025 | 0.8% | |
| Auto Order as % of direct sales product sales volume · direct sales · FY2025 | 62.0% | |
| In-house manufacturing as % of product sales · FY2025 | 56.0% |
Risks flagged
China regulatory and business model risk
“Our Greater China region accounts for a significant part of our business and expected growth. A decline in sales or customers in this region would harm our business, financial condition and results of operations.” · word for word
FTC regulatory risk for direct selling
“In 2025, the FTC issued a Notice of Proposed Rulemaking ("NPR") and an Advanced Notice of Proposed Rulemaking ("ANPR") regarding potential rules for earnings claims for direct selling companies.” · word for word
Dependence on Brand Partners
“If we are unable to attract and retain active Brand Partners and Preferred Customers, our business may be harmed.” · word for word
18 Feb 20268-K · 2.02, 7.01Net sales $226M (+6% y/y); Net loss $-2M; Diluted EPS $-0.10; Guidance: FY2026 net sales guidance of $925M-$1.0B (flat to 8% growth); adjusted diluted EPS $1.95-$2.29.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q4-2025 | $226M | +6% y/y |
| Net loss · Q4-2025 | $-2M | |
| Diluted EPS · Q4-2025 | $-0.10 | |
| Adjusted diluted EPS · Q4-2025 | $0.60 | -6% y/y |
| Adjusted EBITDA · Q4-2025 | $27M | +7% y/y |
| Net sales · FY2025 | $925M | +8% y/y |
| Net earnings · FY2025 | $11M | -74% y/y |
| Diluted EPS · FY2025 | $0.58 | -74% y/y |
| Adjusted diluted EPS · FY2025 | $1.93 | -25% y/y |
| Adjusted EBITDA · FY2025 | $101M | -8% y/y |
Guidance
FY2026 net sales guidance of $925M-$1.0B (flat to 8% growth); adjusted diluted EPS $1.95-$2.29.
Guidance implies modest top-line growth but continued profitability pressure; management optimistic about diversification.
Risks flagged
Core nutritional business active customers declining 15% YoY, indicating structural challenges in direct selling model.
“USANA Active Customers of 387,000, down 15% from 454,000 in prior year.”
Inventory increased 48% to $107M, driven by Rise brand growth and in-sourcing of Hiya production, posing working capital risk.
“Inventory totaled $107 million, an increase of approximately $35 million, or 48% compared to balances at year-end 2024.” · word for word
12 Jan 20268-K · 2.02, 7.01Preliminary Net Sales FY2025 $925M; Preliminary Core Nutritional Net Sales FY2025 $777M; Preliminary Hiya Net Sales FY2025 $132M; Guidance: FY2025 preliminary ~$925M vs prior guidance ~$920M; FY2026 guidance $925M-$1.0Bearningsopen
Figures in the filing · each found in the filing text
| Preliminary Net Sales FY2025 · FY2025 | $925M | |
| Preliminary Core Nutritional Net Sales FY2025 · Core Nutritional · FY2025 | $777M | |
| Preliminary Hiya Net Sales FY2025 · Hiya · FY2025 | $132M | |
| Preliminary Rise Wellness Net Sales FY2025 · Rise Wellness · FY2025 | $16M |
Guidance
FY2025 preliminary ~$925M vs prior guidance ~$920M; FY2026 guidance $925M-$1.0B
FY2025 slightly above prior guidance; FY2026 guidance reflects core decline but growth in Hiya and Rise Wellness; investments pressure margins.
Risks flagged
Core nutritional business declining; reliance on Hiya and Rise Wellness for growth.
“Core nutritional business expected $720-765M vs ~$777M preliminary FY2025.”
Rise Wellness operating at breakeven; investments may not yield expected returns.
“Operating margins in this business are expected to be at breakeven in fiscal 2026.” · word for word
Fiscal 2026 is a 52-week year, one week less of net sales compared to fiscal 2025, impacting core business.
“Fiscal 2026 is a 52-week year, one week less of net sales compared to fiscal 2025 (impacts the core nutritional business).” · word for word
8 Jan 20268-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)open
Risks flagged
Leadership transition may cause short-term uncertainty or strategic shifts.
“CEO transition with former CEO returning; no details on compensation or strategic changes.”
5 Nov 202510-QUSANA reported Q3 2025 results with consolidated net sales up 6.7% YoY to $213.7M, but direct selling net sales declined 8.7% YoY, and a net loss of $6.5M was recorded due to a sharp increase in the effective tax rate to 65%.earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Consolidated · Q3-2025 | $214M | +7% y/y |
| Net Sales - Direct Selling · Direct Selling · Q3-2025 | $183M | -9% y/y |
| Net Sales - Hiya · Hiya · Q3-2025 | $31M | |
| Active Customers - Direct Selling · Direct Selling · Q3-2025 | 388,000 | -14% y/y |
| Active Monthly Subscribers - Hiya · Hiya · Q3-2025 | 193,400 | |
| Gross Profit Margin · Consolidated · Q3-2025 | 77.2% | |
| Net Income (Loss) Attributable to USANA · Q3-2025 | $-7M | |
| Diluted Earnings (Loss) per Share · Q3-2025 | $-0.36 | |
| Cash and Cash Equivalents · Q3-2025 | $145M | |
| Operating Cash Flow · 9M-2025 | $26M | -53% y/y |
Risks flagged
Direct Selling Customer Attrition
“Active Customers in this region declined 14.4% year-over-year” · word for word
Tax Rate Volatility
“The year-to-date effective tax rate increased to 65.0% from the 43.0% reported in the comparable period of fiscal 2024.” · word for word
Compensation Plan Transition Risk
“While we expected a slowdown during this transition, it was more pronounced than anticipated.” · word for word
China Cash Repatriation Risk
“If SAFE or other Chinese regulators introduce new regulations or change existing regulations which allow foreign investors to remit profits and dividends earned in China to other countries, our ability to remit profits or pay dividends from China to the United States may be limited in the future.” · word for word
USANA Health Sciences, Inc. — questions
- What did USANA Health Sciences, Inc. file recently?
- 13 SEC filings in the last 12 months. Latest: 8-K on 2026-10-05 — USANA amended its credit agreement, increasing leverage via a material direct financial obligation.
Every figure on this page comes from USANA Health Sciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.